默沙东接近收购流感药物制造商Cidara Therapeutics

老虎资讯综合
Nov 14, 2025

据英国《金融时报》周四报道,引述知情人士的消息,默沙东集团(Merck & Company Inc) (NYSE:MRK)在对Cidara Therapeutics Inc (NASDAQ:CDTX)的竞购战中领先竞争对手,接近达成收购这家流感治疗药物制造商的交易。

《金融时报》报道称,Cidara的估值可能会高于其33亿美元的市值,交易最快可能于周五宣布。默沙东集团可能仍在与另一家制药公司竞争收购,交易的确切价值尚不清楚。

在这一消息公布后,Cidara股价在盘后交易中上涨近39%。默沙东下跌1.6%。

此次收购是默沙东集团寻求弥补其癌症药物Keytruda潜在收入损失的举措,该药物将于2028年专利到期。该公司7月份同意以100亿美元收购生物技术公司Verona Pharma。

默沙东集团的这笔交易也是在制药板块并购活动加剧的背景下进行的,多家公司争相抢购有前景的药物候选产品。本月早些时候,辉瑞制药(Pfizer Inc) (NYSE:PFE)和诺和诺德公司(Novo Nordisk A/S) (NYSE:NVO)围绕减肥药物制造商Metsera Inc (NASDAQ:MTSR)展开了激烈的竞购战,最终辉瑞制药以100亿美元的交易胜出。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10